FATE
Fate Therapeutics IncCompany with tickers: FATE
Market Cap
$245.36M
Shares Outstanding
116,559,186
CIK
1434316
CUSIP
31189P102
13F Activity (30d)
5 filings
4 filers
Investor Relations
Investor relations
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Laura J. Hamill | Class I Director | Appointed | 2026-06-15 |
| Karin Jooss, Ph.D. | Class I Director | Appointed | 2026-06-15 |
| Robert S. Epstein, M.D., M.S. | Class I Director | Appointed | 2026-06-15 |